Cardiovascular  ||| S:0 E:15 ||| JJ
magnetic  ||| S:15 E:24 ||| JJ
resonance  ||| S:24 E:34 ||| NN
for  ||| S:34 E:38 ||| IN
amyloidosis  ||| S:38 E:50 ||| JJ
Cardiac  ||| S:50 E:58 ||| JJ
involvement  ||| S:58 E:70 ||| NN
drives  ||| S:70 E:77 ||| VBZ
the  ||| S:77 E:81 ||| DT
prognosis  ||| S:81 E:91 ||| NN
and  ||| S:91 E:95 ||| CC
treatment  ||| S:95 E:105 ||| NN
in  ||| S:105 E:108 ||| IN
systemic  ||| S:108 E:117 ||| JJ
amyloid ||| S:117 E:124 ||| NN
.  ||| S:124 E:126 ||| .
Echocardiography ||| S:126 E:142 ||| NNP
,  ||| S:142 E:144 ||| ,
the  ||| S:144 E:148 ||| DT
mainstay  ||| S:148 E:157 ||| NN
of  ||| S:157 E:160 ||| IN
current  ||| S:160 E:168 ||| JJ
cardiac  ||| S:168 E:176 ||| JJ
imaging ||| S:176 E:183 ||| NN
,  ||| S:183 E:185 ||| ,
defines  ||| S:185 E:193 ||| VBZ
cardiac  ||| S:193 E:201 ||| JJ
structure  ||| S:201 E:211 ||| NN
and  ||| S:211 E:215 ||| CC
function ||| S:215 E:223 ||| NN
.  ||| S:223 E:225 ||| .
Echocardiography ||| S:225 E:241 ||| NNP
,  ||| S:241 E:243 ||| ,
in  ||| S:243 E:246 ||| IN
conjunction  ||| S:246 E:258 ||| NN
with  ||| S:258 E:263 ||| IN
clinical  ||| S:263 E:272 ||| JJ
phenotype ||| S:272 E:281 ||| NN
,  ||| S:281 E:283 ||| ,
electrocardiogram  ||| S:283 E:301 ||| NN
and  ||| S:301 E:305 ||| CC
biomarkers  ||| S:305 E:316 ||| NNS
( ||| S:316 E:317 ||| -LRB-
brain  ||| S:317 E:323 ||| FW
natriuretic  ||| S:323 E:335 ||| FW
peptide  ||| S:335 E:343 ||| FW
and  ||| S:343 E:347 ||| CC
troponin ||| S:347 E:355 ||| CD
) ||| S:355 E:356 ||| -RRB-
,  ||| S:356 E:358 ||| ,
provides  ||| S:358 E:367 ||| VBZ
an  ||| S:367 E:370 ||| DT
assessment  ||| S:370 E:381 ||| NN
of  ||| S:381 E:384 ||| IN
the  ||| S:384 E:388 ||| DT
likelihood  ||| S:388 E:399 ||| NN
and  ||| S:399 E:403 ||| CC
extent  ||| S:403 E:410 ||| NN
of  ||| S:410 E:413 ||| IN
cardiac  ||| S:413 E:421 ||| JJ
involvement ||| S:421 E:432 ||| NN
.  ||| S:432 E:434 ||| .
Two  ||| S:434 E:438 ||| CD
tests  ||| S:438 E:444 ||| NNS
are  ||| S:444 E:448 ||| VBP
transforming  ||| S:448 E:461 ||| VBG
our  ||| S:461 E:465 ||| PRP$
understanding  ||| S:465 E:479 ||| NN
of  ||| S:479 E:482 ||| IN
cardiac  ||| S:482 E:490 ||| JJ
amyloidosis ||| S:490 E:501 ||| NN
,  ||| S:501 E:503 ||| ,
bone  ||| S:503 E:508 ||| FW
tracer  ||| S:508 E:515 ||| FW
scanning  ||| S:515 E:524 ||| FW
and  ||| S:524 E:528 ||| CC
cardiovascular  ||| S:528 E:543 ||| JJ
magnetic  ||| S:543 E:552 ||| JJ
resonance  ||| S:552 E:562 ||| NN
( ||| S:562 E:563 ||| -LRB-
CMR ||| S:563 E:566 ||| NNP
) ||| S:566 E:567 ||| -RRB-
.  ||| S:567 E:569 ||| .
CMR  ||| S:569 E:573 ||| NNP
provides  ||| S:573 E:582 ||| VBZ
a  ||| S:582 E:584 ||| DT
second  ||| S:584 E:591 ||| JJ
opinion  ||| S:591 E:599 ||| NN
on  ||| S:599 E:602 ||| IN
the  ||| S:602 E:606 ||| DT
heart ||| S:606 E:611 ||| NN
's  ||| S:611 E:614 ||| POS
structure  ||| S:614 E:624 ||| NN
and  ||| S:624 E:628 ||| CC
systolic  ||| S:628 E:637 ||| JJ
function  ||| S:637 E:646 ||| NN
with  ||| S:646 E:651 ||| IN
better  ||| S:651 E:658 ||| JJR
accuracy  ||| S:658 E:667 ||| NN
and  ||| S:667 E:671 ||| CC
more  ||| S:671 E:676 ||| JJR
precision  ||| S:676 E:686 ||| NN
than  ||| S:686 E:691 ||| IN
echocardiography  ||| S:691 E:708 ||| NN
but  ||| S:708 E:712 ||| CC
is  ||| S:712 E:715 ||| VBZ
unable  ||| S:715 E:722 ||| JJ
to  ||| S:722 E:725 ||| TO
assess  ||| S:725 E:732 ||| VB
diastolic  ||| S:732 E:742 ||| JJ
function  ||| S:742 E:751 ||| NN
and  ||| S:751 E:755 ||| CC
is  ||| S:755 E:758 ||| VBZ
not  ||| S:758 E:762 ||| RB
as  ||| S:762 E:765 ||| RB
widely  ||| S:765 E:772 ||| RB
available ||| S:772 E:781 ||| JJ
.  ||| S:781 E:783 ||| .
Where  ||| S:783 E:789 ||| WRB
CMR  ||| S:789 E:793 ||| NNP
adds  ||| S:793 E:798 ||| VBZ
unique  ||| S:798 E:805 ||| JJ
advantages  ||| S:805 E:816 ||| NNS
is  ||| S:816 E:819 ||| VBZ
in  ||| S:819 E:822 ||| IN
evaluating  ||| S:822 E:833 ||| VBG
myocardial  ||| S:833 E:844 ||| JJ
tissue  ||| S:844 E:851 ||| NN
characterisation ||| S:851 E:867 ||| NN
.  ||| S:867 E:869 ||| .
With  ||| S:869 E:874 ||| IN
administration  ||| S:874 E:889 ||| NN
of  ||| S:889 E:892 ||| IN
contrast ||| S:892 E:900 ||| NN
,  ||| S:900 E:902 ||| ,
the  ||| S:902 E:906 ||| DT
latest  ||| S:906 E:913 ||| JJS
type  ||| S:913 E:918 ||| NN
of  ||| S:918 E:921 ||| IN
late  ||| S:921 E:926 ||| JJ
gadolinium  ||| S:926 E:937 ||| JJ
enhancement  ||| S:937 E:949 ||| NN
imaging  ||| S:949 E:957 ||| NN
( ||| S:957 E:958 ||| -LRB-
phase-sensitive  ||| S:958 E:974 ||| JJ
inversion  ||| S:974 E:984 ||| JJ
recovery  ||| S:984 E:993 ||| NN
sequence ||| S:993 E:1001 ||| NN
)  ||| S:1001 E:1003 ||| -RRB-
is  ||| S:1003 E:1006 ||| VBZ
highly  ||| S:1006 E:1013 ||| RB
sensitive  ||| S:1013 E:1023 ||| JJ
and  ||| S:1023 E:1027 ||| CC
specific  ||| S:1027 E:1036 ||| JJ
with  ||| S:1036 E:1041 ||| IN
images  ||| S:1041 E:1048 ||| NNS
virtually  ||| S:1048 E:1058 ||| RB
pathognomonic  ||| S:1058 E:1072 ||| VBN
for  ||| S:1072 E:1076 ||| IN
amyloidosis ||| S:1076 E:1087 ||| NN
.  ||| S:1087 E:1089 ||| .
CMR  ||| S:1089 E:1093 ||| NNP
is  ||| S:1093 E:1096 ||| VBZ
also  ||| S:1096 E:1101 ||| RB
demonstrating  ||| S:1101 E:1115 ||| VBG
that  ||| S:1115 E:1120 ||| IN
the  ||| S:1120 E:1124 ||| DT
range  ||| S:1124 E:1130 ||| NN
of  ||| S:1130 E:1133 ||| IN
structural  ||| S:1133 E:1144 ||| JJ
and  ||| S:1144 E:1148 ||| CC
functional  ||| S:1148 E:1159 ||| JJ
changes  ||| S:1159 E:1167 ||| NNS
in  ||| S:1167 E:1170 ||| IN
cardiac  ||| S:1170 E:1178 ||| JJ
amyloid  ||| S:1178 E:1186 ||| NN
is  ||| S:1186 E:1189 ||| VBZ
broader  ||| S:1189 E:1197 ||| JJR
than  ||| S:1197 E:1202 ||| IN
traditionally  ||| S:1202 E:1216 ||| RB
thought ||| S:1216 E:1223 ||| VBD
.  ||| S:1223 E:1225 ||| .
CMR  ||| S:1225 E:1229 ||| NNP
with  ||| S:1229 E:1234 ||| IN
T1  ||| S:1234 E:1237 ||| CD
mapping ||| S:1237 E:1244 ||| NN
,  ||| S:1244 E:1246 ||| ,
a  ||| S:1246 E:1248 ||| DT
relatively  ||| S:1248 E:1259 ||| RB
new  ||| S:1259 E:1263 ||| JJ
CMR  ||| S:1263 E:1267 ||| NNP
technique ||| S:1267 E:1276 ||| NN
,  ||| S:1276 E:1278 ||| ,
can  ||| S:1278 E:1282 ||| MD
measure  ||| S:1282 E:1290 ||| VB
the  ||| S:1290 E:1294 ||| DT
amyloid  ||| S:1294 E:1302 ||| JJ
burden  ||| S:1302 E:1309 ||| NN
and  ||| S:1309 E:1313 ||| CC
the  ||| S:1313 E:1317 ||| DT
myocyte  ||| S:1317 E:1325 ||| JJ
response  ||| S:1325 E:1334 ||| NN
to  ||| S:1334 E:1337 ||| TO
infiltration  ||| S:1337 E:1350 ||| VB
( ||| S:1350 E:1351 ||| -LRB-
hypertrophy ||| S:1351 E:1362 ||| CD
/ ||| S:1362 E:1363 ||| CD
cell  ||| S:1363 E:1368 ||| NN
loss ||| S:1368 E:1372 ||| NN
)  ||| S:1372 E:1374 ||| -RRB-
with  ||| S:1374 E:1379 ||| IN
advantages  ||| S:1379 E:1390 ||| NNS
for  ||| S:1390 E:1394 ||| IN
tracking  ||| S:1394 E:1403 ||| VBG
change  ||| S:1403 E:1410 ||| NN
( ||| S:1410 E:1411 ||| -LRB-
e.g.  ||| S:1411 E:1416 ||| CD
the  ||| S:1416 E:1420 ||| DT
wall  ||| S:1420 E:1425 ||| NN
thickness  ||| S:1425 E:1435 ||| NN
can  ||| S:1435 E:1439 ||| MD
stay  ||| S:1439 E:1444 ||| VB
the  ||| S:1444 E:1448 ||| DT
same  ||| S:1448 E:1453 ||| JJ
but  ||| S:1453 E:1457 ||| CC
the  ||| S:1457 E:1461 ||| DT
composition  ||| S:1461 E:1473 ||| NN
can  ||| S:1473 E:1477 ||| MD
change ||| S:1477 E:1483 ||| VB
)  ||| S:1483 E:1485 ||| -RRB-
over  ||| S:1485 E:1490 ||| IN
time  ||| S:1490 E:1495 ||| NN
or  ||| S:1495 E:1498 ||| CC
during  ||| S:1498 E:1505 ||| IN
therapy ||| S:1505 E:1512 ||| NN
.  ||| S:1512 E:1514 ||| .
Such  ||| S:1514 E:1519 ||| JJ
techniques  ||| S:1519 E:1530 ||| NNS
hold  ||| S:1530 E:1535 ||| VBP
great  ||| S:1535 E:1541 ||| JJ
promise  ||| S:1541 E:1549 ||| NN
for  ||| S:1549 E:1553 ||| IN
advancing  ||| S:1553 E:1563 ||| VBG
drug  ||| S:1563 E:1568 ||| NN
development  ||| S:1568 E:1580 ||| NN
in  ||| S:1580 E:1583 ||| IN
this  ||| S:1583 E:1588 ||| DT
arena  ||| S:1588 E:1594 ||| NN
and  ||| S:1594 E:1598 ||| CC
providing  ||| S:1598 E:1608 ||| VBG
new  ||| S:1608 E:1612 ||| JJ
prognostic  ||| S:1612 E:1623 ||| JJ
insights ||| S:1623 E:1631 ||| NNS
.  ||| S:1631 E:1633 ||| .
CMR  ||| S:1633 E:1637 ||| NNP
with  ||| S:1637 E:1642 ||| IN
tissue  ||| S:1642 E:1649 ||| NN
characterisation  ||| S:1649 E:1666 ||| NN
is  ||| S:1666 E:1669 ||| VBZ
rewriting  ||| S:1669 E:1679 ||| VBG
our  ||| S:1679 E:1683 ||| PRP$
understanding  ||| S:1683 E:1697 ||| NN
of  ||| S:1697 E:1700 ||| IN
cardiac  ||| S:1700 E:1708 ||| JJ
amyloidosis  ||| S:1708 E:1720 ||| NN
and  ||| S:1720 E:1724 ||| CC
may  ||| S:1724 E:1728 ||| MD
lead  ||| S:1728 E:1733 ||| VB
to  ||| S:1733 E:1736 ||| TO
the  ||| S:1736 E:1740 ||| DT
development  ||| S:1740 E:1752 ||| NN
of  ||| S:1752 E:1755 ||| IN
new  ||| S:1755 E:1759 ||| JJ
classification ||| S:1759 E:1773 ||| NN
,  ||| S:1773 E:1775 ||| ,
therapies  ||| S:1775 E:1785 ||| NNS
and  ||| S:1785 E:1789 ||| CC
prognostic  ||| S:1789 E:1800 ||| JJ
systems ||| S:1800 E:1807 ||| NNS
.  ||| S:1807 E:1809 ||| .
